XIANXIAO ZHOU

Dr. XIANXIAO ZHOU


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
AMAndrew T. McKenzie
Andrew T. McKenzie
SMSarah Moyon
Sarah Moyon
MWMinghui Wang
Minghui Wang
IKIgor Katsyv
Igor Katsyv
WSWon-Min Song
Won-Min Song
BZBin Zhang
Bin Zhang
Oligodendrocytes (OLs) and myelin are critical for normal brain function and have been implicated in neurodegeneration. Several lines of evidence including neuroimaging and neuropathological data suggest that Alzheimer’s disease (AD) may be associated with dysmyelination and a breakdown of OL-axon communication. In order to understand this phenomenon on a molecular level, we systematically interrogated OL-enriched gene networks constructed from large-scale genomic, transcriptomic and proteomic data obtained from human AD postmortem brain samples. We then validated these networks using gene expression datasets generated from mice with ablation of major gene expression nodes identified in our AD-dysregulated networks. The robust OL gene coexpression networks that we identified were highly enriched for genes associated with AD risk variants, such as BIN1 and demonstrated strong dysregulation in AD. We further corroborated the structure of the corresponding gene causal networks using datasets generated from the brain of mice with ablation of key network drivers, such as UGT8, CNP and PLP1, which were identified from human AD brain data. Further, we found that mice with genetic ablations of Cnp mimicked aspects of myelin and mitochondrial gene expression dysregulation seen in brain samples from patients with AD, including decreased protein expression of BIN1 and GOT2. This study provides a molecular blueprint of the dysregulation of gene expression networks of OL in AD and identifies key OL- and myelination-related genes and networks that are highly associated with AD.

2 March 2022 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
MWMinghui Wang
Minghui Wang
WSWon-Min Song
Won-Min Song
CMChen Ming
Chen Ming
QWQian Wang
Qian Wang
XZXIANXIAO ZHOU
XIANXIAO ZHOU
BZBin Zhang
Bin Zhang
Alzheimer’s disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration. Extensive clinical and genomic studies have revealed biomarkers, risk factors, pathways, and targets of AD in the past decade. However, the exact molecular basis of AD development and progression remains elusive. The emerging single-cell sequencing technology can potentially provide cell-level insights into the disease. Here we systematically review the state-of-the-art bioinformatics approaches to analyze single-cell sequencing data and their applications to AD in 14 major directions, including 1) quality control and normalization, 2) dimension reduction and feature extraction, 3) cell clustering analysis, 4) cell type inference and annotation, 5) differential expression, 6) trajectory inference, 7) copy number variation analysis, 8) integration of single-cell multi-omics, 9) epigenomic analysis, 10) gene network inference, 11) prioritization of cell subpopulations, 12) integrative analysis of human and mouse sc-RNA-seq data, 13) spatial transcriptomics, and 14) comparison of single cell AD mouse model studies and single cell human AD studies. We also address challenges in using human postmortem and mouse tissues and outline future developments in single cell sequencing data analysis. Importantly, we have implemented our recommended workflow for each major analytic direction and applied them to a large single nucleus RNA-sequencing (snRNA-seq) dataset in AD. Key analytic results are reported while the scripts and the data are shared with the research community through GitHub. In summary, this comprehensive review provides insights into various approaches to analyze single cell sequencing data and offers specific guidelines for study design and a variety of analytic directions. The review and the accompanied software tools will serve as a valuable resource for studying cellular and molecular mechanisms of AD, other diseases, or biological systems at the single cell level.

1 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MWMinghui Wang
Minghui Wang
ALAiqun Li
Aiqun Li
MSMichiko Sekiya
Michiko Sekiya
NBNoam D. Beckmann
Noam D. Beckmann
XQXiuming Quan
Xiuming Quan
BZBin Zhang
Bin Zhang
SUMMARY: To study the molecular mechanisms driving the pathogenesis and identify novel therapeutic targets of late onset Alzheimer’s Disease (LOAD), we performed an integrative network analysis of whole-genome DNA and RNA sequencing profiling of four cortical areas, including the parahippocampal gyrus, across 364 donors spanning the full spectrum of LOAD-related cognitive and neuropathological disease severities. Our analyses revealed thousands of molecular changes and uncovered for the first-time multiple neuron specific gene subnetworks most dysregulated in LOAD. ATP6V1A , a critical subunit of vacuolar-type H + -ATPase (v-ATPase), was predicted to be a key regulator of one neuronal subnetwork and its role in disease-related processes was evaluated through CRISPR-based manipulation of human induced pluripotent stem cell derived neurons and RNAi-based knockdown in transgenic Drosophila models. This study advances our understanding of LOAD pathogenesis by providing the global landscape and detailed circuits of complex molecular interactions and regulations in several key brain regions affected by LOAD and the resulting network models provide a blueprint for developing next generation therapeutics against LOAD.

22 November 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
XZXIANXIAO ZHOU
XIANXIAO ZHOU
LWLing Wu
Ling Wu
MWMinghui Wang
Minghui Wang
GWGuojun Wu
Guojun Wu
BZBin Zhang
Bin Zhang
Combination therapy has become increasingly important for treating complex diseases which often involve multiple pathways and targets. However, experimental screening of drug combinations is costly and time-consuming. The availability of large-scale transcriptomic datasets (e.g. CMap and LINCS) from in vitro drug treatment experiments makes it possible to computationally predict drug combinations with synergistic effects. Towards this end, we developed a computational approach, termed Identification of Drug Combinations via Multi-Set Operations (iDOMO), to predict drug synergy based on multi-set operations of drug and disease gene signatures. iDOMO quantifies the synergistic effect of a pair of drugs by taking into account the combination’s beneficial and detrimental effects on treating a disease. We evaluated iDOMO, in a DREAM Challenge dataset with the matched, pre- and post-treatment gene expression data and cell viability information. We further evaluated the performance of iDOMO by concordance index and Spearman correlation on predicting the Highest Single Agency (HSA) synergy scores for four most common cancer types in two large-scale drug combination databases, showing that iDOMO significantly outperformed two existing popular drug combination approaches including the Therapeutic Score and the SynergySeq Orthogonality Score. Application of iDOMO to triple-negative breast cancer (TNBC) identified drug pairs with potential synergistic effects, with the combination of trifluridine and monobenzone being the most synergistic. Our in vitro experiments confirmed that the top predicted drug combination exerted a significant synergistic effect in inhibiting TNBC cell growth. In summary, iDOMO is an effective method for the in silico screening of synergistic drug combinations and will be a valuable tool for the development of novel therapeutics for complex diseases.

30 August 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
ZLZachary S. Lorsch
Zachary S. Lorsch
PHPeter J. Hamilton
Peter J. Hamilton
ARAarthi Ramakrishnan
Aarthi Ramakrishnan
EPEric M. Parise
Eric M. Parise
WWWilliam J. Wright
William J. Wright
ENEric J Nestler
Eric J Nestler
Summary: Stress resilience involves numerous brain-wide transcriptional changes. Determining the organization and orchestration of these transcriptional events may reveal novel antidepressant targets, but this remains unexplored. Here, we characterize the resilient transcriptome with co-expression analysis and identify a single transcriptionally-active uniquely-resilient gene network. Zfp189 , a previously unstudied zinc finger protein, is the top network key driver and its overexpression in prefrontal cortical (PFC) neurons preferentially activates this network, alters neuronal activity and promotes behavioral resilience. CREB, which binds Zfp189 , is the top upstream regulator of this network. To probe CREB- Zfp189 interactions as a network regulatory mechanism, we employ CRISPR-mediated locus-specific transcriptional reprogramming to direct CREB selectively to the Zfp189 promoter. This single molecular interaction in PFC neurons recapitulates the pro-resilient Zfp189- dependent downstream effects on gene network activity, electrophysiology and behavior. These findings reveal an essential role for Zfp189 and a CREB- Zfp189 regulatory axis in mediating a central transcriptional network of resilience.